Bimatol0.03%

Bimatol is a prostaglandin (prostamide) analog with two established uses depending on formulation and strength:

• Reduction of elevated intraocular pressure (IOP) (FDA-approved, first-line/adjunctive topical therapy): indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, used alone or in patients who have had an insufficient response to another intraocular pressure-lowering medication.
• Hypotrichosis of the eyelashes (FDA-approved, cosmetic indication, lower-concentration topical formulation applied to the eyelid margin): indicated to increase the growth of eyelashes, including length, thickness, and darkness, in patients with insufficient or thin eyelashes.

Bimatol ophthalmic solution is not approved for use in angle-closure, inflammatory, or neovascular glaucoma, and is not a substitute for surgical intervention when the latter is indicated.

Each mL of ophthalmic solution contains Bimatoprost (as the active ingredient) 0.01% w/v or 0.03% w/v, depending on brand/formulation, along with benzalkonium chloride as preservative and other inactive ingredients (sodium chloride, sodium phosphate dibasic, citric acid, and purified water) to adjust tonicity and pH. The eyelash-growth formulation similarly contains Bimatoprost 0.03% w/v supplied with a sterile single-use-per-eyelid applicator.

Bimatol is a synthetic prostamide structurally related to prostaglandin F2α. It is formulated as a sterile, preserved topical ophthalmic solution used once daily to lower intraocular pressure in glaucoma and ocular hypertension, and as a lower-concentration topical solution applied to the upper eyelid margin to promote eyelash growth. Bimatol is one of the most widely prescribed prostaglandin-class agents for chronic intraocular pressure control because of its once-daily dosing and significant IOP-lowering effect.

Bimatol belongs to the prostaglandin analog (prostamide) class of ophthalmic antiglaucoma agents. It is grouped with other prostaglandin analogs such as latanoprost, travoprost, and tafluprost, which share a similar mechanism of lowering intraocular pressure by increasing aqueous humor outflow.

Bimatoprost is believed to lower intraocular pressure by increasing the outflow of aqueous humor through both the trabecular meshwork (conventional outflow pathway) and the uveoscleral (unconventional) outflow pathway. Unlike drugs that primarily act as prostaglandin receptor agonists, Bimatoprost is a synthetic prostamide whose exact receptor pharmacology differs somewhat from classical prostaglandin analogs, though the net clinical effect is comparable IOP reduction.

Onset of IOP-lowering action begins approximately 4 hours after ocular administration, with peak effect seen at 8 to 12 hours. For the eyelash-growth indication, Bimatoprost is thought to increase the proportion and duration of hair follicles in the anagen (growth) phase and to increase follicle size, resulting in longer, thicker, and darker eyelashes with continued use.

Bimatoprost undergoes minimal systemic absorption when applied topically to the eye or eyelid margin, resulting in very low systemic drug levels.

Bimatol ophthalmic solution is for topical ophthalmic (eye-drop) use only.

• Wash hands before use; avoid letting the dropper tip touch the eye, eyelid, or any other surface to prevent contamination.
• Tilt the head back, pull down the lower eyelid to form a pocket, and instill one drop into the affected eye(s).
• If using other topical ophthalmic products at the same time, space administration of each product at least 5 minutes apart.
• If wearing contact lenses, remove them before instillation (the solution contains benzalkonium chloride, which can be absorbed by soft contact lenses) and wait at least 15 minutes before reinserting.

For the eyelash-growth formulation, apply only to the upper eyelid margin using the accompanying single-use applicator; never apply Bimatol to the lower lid, and avoid contact with other areas of skin or the eye itself.

No clinically significant systemic drug-drug interactions have been well established for Bimatol due to its minimal systemic absorption. Points relevant to interaction/co-administration include:

• Other topical ophthalmic products: if using more than one topical eye medication, doses should be spaced at least 5 minutes apart to prevent one product from washing out another.
• Other prostaglandin analogs: concurrent use of two prostaglandin/prostamide analogs (e.g. two different IOP-lowering prostaglandin eye drops) is not recommended, as this has been associated with a paradoxical increase in IOP in some cases and offers no added benefit.

The most common adverse effect of Bimatol ophthalmic solution is conjunctival hyperemia (eye redness), reported in a substantial proportion of patients, usually mild.

• Ocular itching (pruritus) and irritation
• Growth, thickening, and darkening of eyelashes (expected with the eyelash-growth product; may also occur with the glaucoma-indicated solution)
• Darkening (increased pigmentation) of the periorbital skin/eyelid
• Increased brown pigmentation of the iris (see Precautions and Warnings)
• Dry eye, burning or foreign body sensation, eyelid erythema or edema
• Blurred vision, photophobia, increased tearing
• Headache (uncommon)

Most ocular side effects of Bimatol are mild to moderate and localized to the eye/periorbital area.

Pregnancy: There are no adequate and well-controlled studies of Bimatol in pregnant women. Animal reproduction studies have shown adverse effects (including pregnancy loss) at systemic exposures substantially higher than those achieved with topical ocular use in humans. Bimatol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under medical supervision.

Lactation: It is not known whether Bimatol or its metabolites are excreted in human breast milk. Because systemic absorption after topical ocular use is low but not zero, caution is advised, and a decision should be made whether to discontinue breastfeeding or discontinue Bimatol, considering the benefit of the medicine to the mother. Consult a physician before use during breastfeeding.

Pigmentation changes: Bimatol can cause a gradual increase in brown pigmentation of the iris, which is likely permanent and may result in a permanent difference in eye color between eyes if only one eye is treated; this is more noticeable in patients with mixed-color (e.g. green-brown, blue/grey-brown) irises. Darkening of the periorbital skin and eyelid margin may also occur and, unlike iris pigmentation, may be reversible after stopping treatment. Patients should be counseled about these possible permanent changes before starting therapy.

Eyelash and periocular hair changes: gradual increases in eyelash length, thickness, pigmentation, and number of lashes can occur with both the glaucoma-indicated solution and the eyelash-growth product; changes are usually reversible upon discontinuation.

Intraocular inflammation: Bimatol should be used with caution in patients with active intraocular inflammation (e.g. uveitis) or a history of it, as prostaglandin analogs may exacerbate inflammation.

Macular edema: use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with known risk factors for macular edema.

Herpetic keratitis: use with caution in patients with a history of herpetic keratitis; reactivation has been reported rarely with prostaglandin analogs.

Bacterial keratitis: contaminated multi-dose ophthalmic containers have been associated with bacterial keratitis; avoid letting the applicator/dropper tip contact any surface.

Contact lenses and multiple eye products: remove contact lenses before use and wait at least 15 minutes before reinsertion; if using other topical ophthalmic products, space doses at least 5 minutes apart (see Administration).

No specific human data on overdose with Bimatol ophthalmic use are available. If a large amount of Bimatol is accidentally ingested or if excessive ocular use causes concerning symptoms (e.g. marked eye redness, irritation, or systemic symptoms), seek immediate medical attention or contact a poison control center. If accidental instillation of an excessive amount occurs, the eye(s) may be flushed with lukewarm water. Do not attempt specific home treatment beyond this without medical guidance.

Store at room temperature, between 2°C and 25°C (36°F to 77°F), away from direct light. Keep the bottle tightly closed when not in use and discard any unused solution after the labeled in-use period (typically 4 weeks after opening, per product labeling). Keep out of reach of children.

Pediatric use: the safety and efficacy of Bimatol in pediatric patients below the age of 16 years have not been established; use in this population is generally not recommended due to potential concerns including pigmentation changes with long-term exposure. See Pediatric Uses.

Geriatric use: no overall differences in safety or effectiveness have been observed between elderly and younger adult patients; no dose adjustment is required based on age alone.

Renal/hepatic impairment: no formal dose adjustment has been established as necessary, given the minimal systemic absorption of Bimatol after topical ocular or eyelid use; use with routine medical judgment in patients with significant organ impairment.

For glaucoma and ocular hypertension, Bimatol is typically used long-term/chronically to control intraocular pressure, with regular ophthalmologic monitoring of IOP, the optic nerve, and visual fields to assess ongoing benefit. For eyelash hypotrichosis, continued nightly application is needed to maintain the cosmetic effect; if Bimatol is discontinued, eyelashes gradually return to their pretreatment appearance over the course of weeks to a few months. Treatment duration in either case should be guided by a physician based on response and ongoing need.

Prostaglandin analog (prostamide); ophthalmic antiglaucoma agent.

Bimatoprost is a synthetic prostamide that lowers intraocular pressure primarily by increasing aqueous humor outflow through both the trabecular meshwork and the uveoscleral outflow pathway, thereby reducing fluid pressure within the eye. For eyelash growth, Bimatoprost is believed to prolong the anagen (active growth) phase of the hair cycle and increase the number of hairs in this phase, as well as increase hair follicle size, producing longer, thicker, and darker eyelashes.

C

The safety and efficacy of Bimatol have not been established in pediatric patients younger than 16 years for the glaucoma/ocular hypertension indication, and the eyelash-growth formulation is not indicated for use in patients under 18 years of age. Bimatol should generally be avoided in children unless specifically directed by a pediatric ophthalmologist, given limited safety data and theoretical concerns about pigmentation changes with long-term pediatric exposure. Any use in children should be under close specialist supervision.